The Trump administration has been barred from carrying out its sweeping plan to restructure and downsize the Department of ...

Gilead's Trodelvy shows significant improvement in progression-free survival for metastatic triple-negative breast cancer ...

Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech ...

Volastra reports promising Phase 1/2 data for VLS-1488 in solid tumors, with good safety and early efficacy signals in ...

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least ...

Jazz's Zepzelca + Roche's Tecentriq shows 27% reduced death risk & improved survival in lung cancer trial; FDA application ...

The House of Representatives on Thursday passed President Donald Trump’s tax cut package, with steep Medicaid cuts, PBM ...

FDA Commissioner Marty Makary defended thousands of staff cuts during his first congressional hearing since taking office, ...

The White House released its first MAHA Commission report, detailing some of the Trump administration’s top priorities for ...

Endpoints News announces URL change from endpts.com to endpoints.news effective June 1, 2025, with legacy redirects planned ...

Venrock's Healthcare Prognosis survey shows 71% favor AI integration in existing companies over new AI firms, with mixed ...

After a median 34.2 months of follow-up, patients taking Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex survived for a median of 34 months, compared to 27 months for those ...